Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Enliven Therapeutics Ord Shs (ELVN)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 41,210,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   IMARA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies, and other serious diseases. Co.'s pipeline is built on the differentiated therapeutic potential of its primary product candidate, tovinontrine (IMR-687), which is an oral, small molecule inhibitor of phosphodiesterase-9. Tovinontrine is in Phase 2b clinical development for the treatment of sickle cell disease and ss-thalassemia. Co. is also developing IMR-261, an oral, clinic-ready activator of nuclear factor erythroid 2–related factor 2.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 1,441,450
Total Buy Value $0 $0 $0 $5,187,327
Total People Bought 0 0 0 3
Total Buy Transactions 0 0 0 17
Total Shares Sold 1,148,088 1,773,907 2,254,479 4,902,105
Total Sell Value $19,401,421 $28,729,797 $36,315,736 $46,937,826
Total People Sold 8 8 8 10
Total Sell Transactions 29 62 67 78
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 247
  Page 3 of 10  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Kintz Samuel PRESIDENT AND CEO   •       •      –    2024-02-26 4 AS $16.69 $202,653 D/D (12,000) 0     -
   Kintz Samuel PRESIDENT AND CEO   •       •      –    2024-02-26 4 OE $1.12 $13,440 D/D 12,000 12,000     -
   Heyman Richard A.   –       •      –    2024-02-15 4 AS $17.42 $22,117 D/D (1,270) 144,740     -
   Schwab Andrew J. 10% Owner   –       –       •   2024-02-14 4 S $14.90 $12,292,500 I/I (825,000) 635,341     -
   Patel Anish CHIEF OPERATING OFFICER   •       –      –    2024-02-06 4 AS $15.11 $73,658 D/D (4,875) 12,347     -
   Schwab Andrew J. 10% Owner   –       –       •   2024-01-31 4 S $15.00 $7,500,000 I/I (500,000) 771,983     -
   Heyman Richard A.   –       •      –    2024-01-30 4 AS $16.41 $20,840 D/D (1,270) 146,010     -
   Hohl Benjamin CHIEF FINANCIAL OFFICER   •       –      –    2024-01-29 4 AS $15.81 $51,388 D/D (3,250) 0     -
   Hohl Benjamin CHIEF FINANCIAL OFFICER   •       –      –    2024-01-29 4 OE $2.48 $8,060 D/D 3,250 3,250     -
   Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER   •       •      –    2024-01-29 4 AS $15.85 $190,256 D/D (12,000) 0     -
   Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER   •       •      –    2024-01-29 4 OE $1.12 $13,440 D/D 12,000 12,000     -
   Kintz Samuel President and CEO   •       •      –    2024-01-25 4 AS $14.94 $188,229 D/D (12,000) 0     -
   Kintz Samuel President and CEO   •       •      –    2024-01-25 4 OE $1.12 $13,440 D/D 12,000 12,000     -
   Patel Anish Chief Operating Officer   •       –      –    2024-01-22 4 AS $15.14 $73,783 D/D (4,875) 17,222     -
   Patel Anish Chief Operating Officer   •       –      –    2024-01-02 4 AS $15.00 $165,053 D/D (11,000) 22,097     -
   Hohl Benjamin Chief Financial Officer   •       –      –    2024-01-02 4 AS $15.01 $140,839 D/D (9,383) 0     -
   Hohl Benjamin Chief Financial Officer   •       –      –    2024-01-02 4 OE $2.48 $23,270 D/D 9,383 9,383     -
   Lyssikatos Joseph P Chief Scientific Officer   •       •      –    2023-12-29 4 AS $14.13 $171,381 D/D (12,000) 0     -
   Lyssikatos Joseph P Chief Scientific Officer   •       •      –    2023-12-29 4 OE $1.12 $13,440 D/D 12,000 12,000     -
   Patel Anish Chief Operating Officer   •       –      –    2023-12-29 4 AS $15.00 $300 D/D (20) 33,097     -
   Hohl Benjamin Chief Financial Officer   •       –      –    2023-12-29 4 AS $15.00 $300 D/D (20) 0     -
   Hohl Benjamin Chief Financial Officer   •       –      –    2023-12-29 4 OE $2.48 $50 D/D 20 20     -
   Patel Anish Chief Operating Officer   •       –      –    2023-12-28 4 AS $15.08 $37,996 D/D (2,520) 33,117     -
   Hohl Benjamin Chief Financial Officer   •       –      –    2023-12-28 4 AS $15.07 $37,188 D/D (2,467) 0     -
   Hohl Benjamin Chief Financial Officer   •       –      –    2023-12-28 4 OE $2.48 $6,118 D/D 2,467 2,467     -
  247 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 3 of 10
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us